UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2016 UpToDate®

Prognostic factors in patients with renal cell carcinoma

Author
Toni K Choueiri, MD
Section Editors
Jerome P Richie, MD, FACS
Michael B Atkins, MD
Deputy Editor
Michael E Ross, MD

INTRODUCTION

Renal cell carcinomas (RCCs), which originate within the renal cortex, constitute 80 to 85 percent of primary renal neoplasms. Urothelial (transitional cell) carcinomas of the renal pelvis account for approximately 8 percent of kidney tumors, and other parenchymal epithelial tumors, such as oncocytomas, collecting duct tumors, and renal sarcomas, are rare. Nephroblastoma (Wilms' tumor) is common in children (5 to 6 percent of primary renal tumors). (See "Epidemiology, pathology, and pathogenesis of renal cell carcinoma" and "Malignancies of the renal pelvis and ureter".)

When patients with RCC present with localized disease, surgical resection can be curative. Unfortunately, many RCCs are clinically silent for much of their natural history. Thus, the diagnosis is frequently not made until disease is either locally advanced and unresectable or metastatic. Furthermore, many patients who initially are resectable eventually recur. The prognosis for long-term disease-free survival for patients with locally advanced or metastatic RCC is generally poor.

The factors affecting prognosis in patients with RCC will be reviewed here. An overview of the approach to treatment is presented separately. (See "Overview of the treatment of renal cell carcinoma".)

ANATOMIC EXTENT OF DISEASE

The Tumor, Nodes, Metastasis (TNM) staging system is used to assess the anatomic extent of disease (table 1) [1]. The anatomic extent of disease is the most consistent factor that influences prognosis in patients with renal cell carcinoma (RCC) (figure 1). (See "Clinical manifestations, evaluation, and staging of renal cell carcinoma", section on 'TNM staging system'.)

Stage I/II — Patients with stage I RCC have a five-year survival rate over 90 percent in most contemporary series. The survival rate may be slightly lower for patients with stage II disease, with reported five-year survival rates ranging from 75 to 95 percent.

          

Subscribers log in here

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information or to purchase a personal subscription, click below on the option that best describes you:
Literature review current through: Nov 2016. | This topic last updated: Mon Aug 03 00:00:00 GMT+00:00 2015.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2016 UpToDate, Inc.
References
Top
  1. Kidney. In: AJCC Cancer Staging Manual, Springer, New York 2009. p.479.
  2. Verhoest G, Avakian R, Bensalah K, et al. Urinary collecting system invasion is an independent prognostic factor of organ confined renal cell carcinoma. J Urol 2009; 182:854.
  3. Siemer S, Lehmann J, Loch A, et al. Current TNM classification of renal cell carcinoma evaluated: revising stage T3a. J Urol 2005; 173:33.
  4. Gilbert SM, Murphy AM, Katz AE, et al. Reevaluation of TNM staging of renal cortical tumors: recurrence and survival for T1N0M0 and T3aN0M0 tumors are equivalent. Urology 2006; 68:287.
  5. Siddiqui SA, Frank I, Leibovich BC, et al. Impact of tumor size on the predictive ability of the pT3a primary tumor classification for renal cell carcinoma. J Urol 2007; 177:59.
  6. Chevinsky M, Imnadze M, Sankin A, et al. Pathological Stage T3a Significantly Increases Disease Recurrence across All Tumor Sizes in Renal Cell Carcinoma. J Urol 2015; 194:310.
  7. Waters WB, Richie JP. Aggressive surgical approach to renal cell carcinoma: review of 130 cases. J Urol 1979; 122:306.
  8. Ficarra V, Righetti R, D'Amico A, et al. Renal vein and vena cava involvement does not affect prognosis in patients with renal cell carcinoma. Oncology 2001; 61:10.
  9. Hatcher PA, Anderson EE, Paulson DF, et al. Surgical management and prognosis of renal cell carcinoma invading the vena cava. J Urol 1991; 145:20.
  10. Cherrie RJ, Goldman DG, Lindner A, deKernion JB. Prognostic implications of vena caval extension of renal cell carcinoma. J Urol 1982; 128:910.
  11. Anderson CB, Clark PE, Morgan TM, et al. Urinary collecting system invasion is a predictor for overall and disease-specific survival in locally invasive renal cell carcinoma. Urology 2011; 78:99.
  12. Heng DY, Choueiri TK, Rini BI, et al. Outcomes of patients with metastatic renal cell carcinoma that do not meet eligibility criteria for clinical trials. Ann Oncol 2014; 25:149.
  13. Motzer RJ, Hutson TE, McCann L, et al. Overall survival in renal-cell carcinoma with pazopanib versus sunitinib. N Engl J Med 2014; 370:1769.
  14. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013; 369:722.
  15. Patard JJ, Leray E, Rioux-Leclercq N, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol 2005; 23:2763.
  16. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol 2010; 183:1309.
  17. Teloken PE, Thompson RH, Tickoo SK, et al. Prognostic impact of histological subtype on surgically treated localized renal cell carcinoma. J Urol 2009; 182:2132.
  18. Golshayan AR, George S, Heng DY, et al. Metastatic sarcomatoid renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. J Clin Oncol 2009; 27:235.
  19. Tsui KH, Shvarts O, Smith RB, et al. Prognostic indicators for renal cell carcinoma: a multivariate analysis of 643 patients using the revised 1997 TNM staging criteria. J Urol 2000; 163:1090.
  20. Zisman A, Pantuck AJ, Dorey F, et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19:1649.
  21. Medeiros LJ, Gelb AB, Weiss LM. Renal cell carcinoma. Prognostic significance of morphologic parameters in 121 cases. Cancer 1988; 61:1639.
  22. Novara G, Martignoni G, Artibani W, Ficarra V. Grading systems in renal cell carcinoma. J Urol 2007; 177:430.
  23. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6:655.
  24. Rioux-Leclercq N, Karakiewicz PI, Trinh QD, et al. Prognostic ability of simplified nuclear grading of renal cell carcinoma. Cancer 2007; 109:868.
  25. Sengupta S, Lohse CM, Leibovich BC, et al. Histologic coagulative tumor necrosis as a prognostic indicator of renal cell carcinoma aggressiveness. Cancer 2005; 104:511.
  26. Ficarra V, Novara G, Galfano A, et al. The 'Stage, Size, Grade and Necrosis' score is more accurate than the University of California Los Angeles Integrated Staging System for predicting cancer-specific survival in patients with clear cell renal cell carcinoma. BJU Int 2009; 103:165.
  27. Motzer RJ, Mazumdar M, Bacik J, et al. Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 1999; 17:2530.
  28. Suppiah R, Shaheen PE, Elson P, et al. Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer 2006; 107:1793.
  29. Bensalah K, Leray E, Fergelot P, et al. Prognostic value of thrombocytosis in renal cell carcinoma. J Urol 2006; 175:859.
  30. Fahn HJ, Lee YH, Chen MT, et al. The incidence and prognostic significance of humoral hypercalcemia in renal cell carcinoma. J Urol 1991; 145:248.
  31. Patard JJ, Dorey FJ, Cindolo L, et al. Symptoms as well as tumor size provide prognostic information on patients with localized renal tumors. J Urol 2004; 172:2167.
  32. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003; 348:1625.
  33. Siemer S, Hack M, Lehmann J, et al. Outcome of renal tumors in young adults. J Urol 2006; 175:1240.
  34. Zisman A, Pantuck AJ, Wieder J, et al. Risk group assessment and clinical outcome algorithm to predict the natural history of patients with surgically resected renal cell carcinoma. J Clin Oncol 2002; 20:4559.
  35. Yaycioglu O, Roberts WW, Chan T, et al. Prognostic assessment of nonmetastatic renal cell carcinoma: a clinically based model. Urology 2001; 58:141.
  36. Atzpodien J, Royston P, Wandert T, et al. Metastatic renal carcinoma comprehensive prognostic system. Br J Cancer 2003; 88:348.
  37. Sorbellini M, Kattan MW, Snyder ME, et al. A postoperative prognostic nomogram predicting recurrence for patients with conventional clear cell renal cell carcinoma. J Urol 2005; 173:48.
  38. Ramsey S, Lamb GW, Aitchison M, et al. Evaluation of an inflammation-based prognostic score in patients with metastatic renal cancer. Cancer 2007; 109:205.
  39. Zisman A, Pantuck AJ, Figlin RA, Belldegrun AS. Validation of the ucla integrated staging system for patients with renal cell carcinoma. J Clin Oncol 2001; 19:3792.
  40. Takahashi M, Rhodes DR, Furge KA, et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci U S A 2001; 98:9754.
  41. Junker K, Moravek P, Podhola M, et al. Genetic alterations in metastatic renal cell carcinoma detected by comparative genomic hybridization: correlation with clinical and histological data. Int J Oncol 2000; 17:903.
  42. Kosari F, Parker AS, Kube DM, et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005; 11:5128.
  43. Jones J, Otu H, Spentzos D, et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11:5730.
  44. Gonzalgo ML, Yegnasubramanian S, Yan G, et al. Molecular profiling and classification of sporadic renal cell carcinoma by quantitative methylation analysis. Clin Cancer Res 2004; 10:7276.
  45. Thompson RH, Kwon ED. Significance of B7-H1 overexpression in kidney cancer. Clin Genitourin Cancer 2006; 5:206.
  46. Bui MH, Visapaa H, Seligson D, et al. Prognostic value of carbonic anhydrase IX and KI67 as predictors of survival for renal clear cell carcinoma. J Urol 2004; 171:2461.
  47. Klatte T, Seligson DB, Riggs SB, et al. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma. Clin Cancer Res 2007; 13:7388.
  48. Gordan JD, Lal P, Dondeti VR, et al. HIF-alpha effects on c-Myc distinguish two subtypes of sporadic VHL-deficient clear cell renal carcinoma. Cancer Cell 2008; 14:435.
  49. Jiang Z, Chu PG, Woda BA, et al. Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study. Lancet Oncol 2006; 7:556.
  50. Hoffmann NE, Sheinin Y, Lohse CM, et al. External validation of IMP3 expression as an independent prognostic marker for metastatic progression and death for patients with clear cell renal cell carcinoma. Cancer 2008; 112:1471.
  51. Jiang Z, Lohse CM, Chu PG, et al. Oncofetal protein IMP3: a novel molecular marker that predicts metastasis of papillary and chromophobe renal cell carcinomas. Cancer 2008; 112:2676.
  52. La Rochelle J, Klatte T, Dastane A, et al. Chromosome 9p deletions identify an aggressive phenotype of clear cell renal cell carcinoma. Cancer 2010; 116:4696.
  53. Brunelli M, Eccher A, Gobbo S, et al. Loss of chromosome 9p is an independent prognostic factor in patients with clear cell renal cell carcinoma. Mod Pathol 2008; 21:1.
  54. Klatte T, Rao PN, de Martino M, et al. Cytogenetic profile predicts prognosis of patients with clear cell renal cell carcinoma. J Clin Oncol 2009; 27:746.
  55. Presti JC Jr, Wilhelm M, Reuter V, et al. Allelic loss on chromosomes 8 and 9 correlates with clinical outcome in locally advanced clear cell carcinoma of the kidney. J Urol 2002; 167:1464.
  56. Hakimi AA, Ostrovnaya I, Reva B, et al. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network. Clin Cancer Res 2013; 19:3259.
  57. Kapur P, Peña-Llopis S, Christie A, et al. Effects on survival of BAP1 and PBRM1 mutations in sporadic clear-cell renal-cell carcinoma: a retrospective analysis with independent validation. Lancet Oncol 2013; 14:159.
  58. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499:43.
  59. Rini B, Goddard A, Knezevic D, et al. A 16-gene assay to predict recurrence after surgery in localised renal cell carcinoma: development and validation studies. Lancet Oncol 2015; 16:676.
  60. Schutz FA, Pomerantz MM, Gray KP, et al. Single nucleotide polymorphisms and risk of recurrence of renal-cell carcinoma: a cohort study. Lancet Oncol 2013; 14:81.
  61. Validation and genomic interrogation of the MET variant rs11762213 as a predictor of adverse outcomes in clear cell renal cell carcinoma. http://meetinglibrary.asco.org/content/124087-142 (Accessed on May 18, 2015).
  62. Heng DY, Choueiri TK. The evolving landscape of metastatic renal cell carcinoma. Am Soc Clin Oncol Educ Book 2012; :299.
  63. Motzer RJ, Bacik J, Mazumdar M. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience. Clin Cancer Res 2004; 10:6302S.
  64. Mekhail TM, Abou-Jawde RM, Boumerhi G, et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J Clin Oncol 2005; 23:832.
  65. Beuselinck B, Oudard S, Rixe O, et al. Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Ann Oncol 2011; 22:794.
  66. Motzer RJ, Bukowski RM, Figlin RA, et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008; 113:1552.
  67. Heng DY, Chi KN, Murray N, et al. A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer. Cancer 2009; 115:776.
  68. Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009; 27:5794.
  69. Heng DY, Xie W, Regan MM, et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study. Lancet Oncol 2013; 14:141.
  70. Ko JJ, Xie W, Kroeger N, et al. The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study. Lancet Oncol 2015; 16:293.
  71. Kroeger N, Xie W, Lee JL, et al. Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: characterization of survival outcome and application of the International mRCC Database Consortium criteria. Cancer 2013; 119:2999.
  72. Choueiri TK, Garcia JA, Elson P, et al. Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 2007; 110:543.
  73. Manola J, Royston P, Elson P, et al. Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. Clin Cancer Res 2011; 17:5443.
  74. Négrier S, Escudier B, Gomez F, et al. Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: a report from the Groupe Français d'Immunothérapie. Ann Oncol 2002; 13:1460.
  75. Motzer RJ, Bacik J, Murphy BA, et al. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002; 20:289.